Triazolam Chemical Properties

Melting point:

209-212°C

Boiling point:

499.51°C (rough estimate)

Density 

1.2835 (rough estimate)

refractive index 

1.6300 (estimate)

Flash point:

11 °C

storage temp. 

2-8°C

solubility 

DMF: 30 mg/ml; DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml; DMSO: 20 mg/ml; Ethanol: 10 mg/ml

form 

A crystalline solid

pka

pKa 1.52(H2O) (Uncertain);6.5(H2O) (Uncertain)

Water Solubility 

30mg/L(ambient temperature)

CAS DataBase Reference

28911-01-5(CAS DataBase Reference)

NIST Chemistry Reference

Triazolam(28911-01-5)

EPA Substance Registry System

Triazolam (28911-01-5)

Safety Information

Hazard Codes 

F,T

Risk Statements 

11-23/24/25-36/38-39/23/24/25

Safety Statements 

22-24/25-26-36-45-36/37-16-7

RIDADR 

3249

WGK Germany 

2

RTECS 

XZ5472500

HazardClass 

6.1(b)

PackingGroup 

III

HS Code 

2933910000

Hazardous Substances Data

28911-01-5(Hazardous Substances Data)

Toxicity

LD50 in mice, rats (mg/kg): >100, >5000 orally (Pharm. Weekblad.)

MSDS

• Language:English Provider:SigmaAldrich

Triazolam Usage And Synthesis

Chemical Properties

Yellow Solid

Originator

Halcion,Upjohn,Switz.,1978

Uses

Triazolam

Uses

Sedative, hypnotic. Controlled substance (depressant).

Definition

ChEBI: Triazolam is a triazolobenzodiazepine. It has a role as a sedative.

Manufacturing Process

A mixture of 1.0g (0.0031 mol) of 7-chloro-1,3-dihydro-5-(o-chlorophenyl)- 2H-1,4-benzodiazepine-2-thione, 0.8 g (0.0108 mol) of acetic acid hydrazide and 40 ml of 1-butanol was heated at reflux temperature under nitrogen for 24 hours. During the first 5 hours the nitrogen was slowly bubbled through the solution. After cooling and removing the solvent in vacuo, the product was well mixed with water and collected on a filter, giving 0.9 g of orange solid, melting point 210°C to 212°C. This was heated under nitrogen in an oil bath at 250°C and then cooled, The solid was crystallized from ethyl acetate, giving 0.5 g of tan solid of melting point 215°C to 216°C (decomposition). This was dissolved in 25 ml of 2-propanol, filtered, concentrated to10 ml and cooled, yielding 0.46 g (43%) of tan, crystalline 8-chloro-1-methyl-6-(o_x0002_chlorophenyl)-4H-s-triazolo[4,3-a][1,4]-benzodiazepine of melting point 223°C to 225°C.

brand name

Novoderm;Nuctane;Songarn.

Therapeutic Function

Hypnotic

World Health Organization (WHO)

Triazolam, a benzodiazepine derivative with sedative and hypnotic activity, was introduced in 1978 for themanagement of insomnia. It is controlled under Schedule IV of the 1971 Convention of Psychotropic Substances. Concern regarding the psychotropic effects of triazolam was first raised in the Netherlands in 1979 when this compound was suspended for sale and subsequently withdrawn by the Committee for the Evaluation of Medicines on the basis of reports of a reversible complex of symptoms including paranoia, depersonalization, nightmares, suicidal tendency and hyperaesthesia in patients receiving the drug. The basis for this decision was later successfully contested by the manufacturer and the drug was reregistered in early 1990 with a revised product information. However, concern was regenerated elsewhere that higher doses are associated with an unacceptable incidence of unwanted effects and the manufacturer has eventually withdrawn 0.5 mg tablets on a worldwide basis. In 1991 the issue of the safety of triazolam was again reopened by reports of retrograde amnesia and depression among patients taking the decreased recommended dosages. The product information has been revised by the United States FDA to include more rigorous cautions regarding dosage. In the Member States of the European Communities the products have been suspended pending further review by the EC Committee on Proprietary Medicinal Products.

General Description

Triazolam, 8-chloro-6-(o-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4] benzodiazepine(Halcion), has all of the characteristic benzodiazepine pharmacologicalactions. It is an ultra–short-acting hypnoticbecause it is rapidly α-hydroxylated to the 1-methyl alcohol,which is then rapidly conjugated and excreted.Consequently, it has gained popularity as sleep inducers, especiallyin elderly patients, because it causes less daytimesedation. It is metabolically inactivated primarily by hepaticand intestinal CYP3A4; therefore, coadministration withgrapefruit juice increases its peak plasma concentration by30%, leading to increased drowsiness.

Triazolam(28911-01-5)Related Product Information

• 1H-Benzotriazole
• Basic Violet 1
• Methyl acrylate
• Chlorzoxazone
• Paraquat dichloride
• Acetonitrile
• 1,2,4-Triazole
• Cloxacillin-13C4 SodiuM Salt
• Kresoxim-methyl
• Methyltriphenylphosphonium bromide
• Methanol
• 1-CHLOROMETHYL-1H-1,2,4-TRIAZOLE
• Methylparaben
• Methyl acetate
• Dichloromethylphenylsilane
• 5-Methyl-1H-benzotriazole
• Trimethylphenylammonium chloride
• Trazodone